Kosei Pharma Private Limited - Due diligence report

A 360° intelligence report on Kosei Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and di…

2016-11-22 Vadodara, Gujarat Under Process Of Striking Off Unlisted Active Compliant
Share
KP Kosei Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Kosei Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
61/100
Trust Score
Moderate

Kosei Pharma Private Limited is assessed as Moderate with a Trust Score of 61/100. Kosei Pharma Private Limited is a private limited indian non-government company incorporated in 2016, operating in the Healthcare sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.

Report generated on 22 Jul 2026 from the latest processed filings. Kosei Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
61/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
43/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
50/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 43/100 Caution Indicated
  • Company status is "Under Process Of Striking Off" - not Active.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 75/100
NameDIN / PANDesignationAppointedTenureDIN status
Ranjana Chandrashekhar Trivedi 01234567 Director 01/04/2018 6 yrs Approved
RANJEETKUMAR PARMANAND SHARMA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • 4 director exits in 3 years - high churn.
06

Ownership & Group Intelligence

As per FY 2020 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Kosei Pharma(uk) Limited
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Kosei Pharma(uk) Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 50
Growth signals & trust indicators
Profit expanded 1.42 year-on-year.
Asset base grew 2.1x - capacity expansion.
Net margin improved to 24%.
Operating for 9 years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Adverse company status: Under Process Of Striking Off.
Compliance score is weak (43/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence50/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment72/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view68/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
29 Sep 2024
Director ceased
Ranjana Chandrashekhar Trivedi
Director ceased
RANJEETKUMAR PARMANAND SHARMA
31 Mar 2024
Latest balance sheet
Filed with ROC
15 Mar 2024
Director ceased
Soumendranath Ghosh
Director ceased
KOHEI TODA
11 Mar 2024
Director appointed
Ranjana Chandrashekhar Trivedi (Director)
Director appointed
RANJEETKUMAR PARMANAND SHARMA (Director)
06 Aug 2019
Director ceased
Dipak Giri Hem lal Giri
01 Jan 2019
Director ceased
Masabumi Abe
29 Sep 2018
Director ceased
SHAHAJI JAGANNATH JADHAV
25 Apr 2018
Securities allotted
173040 Equity Shares Without Differential Rights - 17.30 Lakh raised
29 Dec 2017
Director ceased
VANDANABEN RAMESHCHANDRA RAVAL
Director ceased
BRIJESHKUMAR PRAVINKUMAR RAJGOR
17 Nov 2017
Securities allotted
82220 Equity Shares Without Differential Rights - 8.22 Lakh raised
10

Key Observations

Auto-generated from the data above
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2020 annual return.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Max Vision Hospitality Private Limited U55204DL2012PTC233901 Delhi, Delhi, India
Envesage 3Dinterior Solutions Private Limited U74999UP2018PTC107594 Greater Noida, Uttar Pradesh, India
Gate Cross Exports Private Limited U51909PY2018PTC008314 Puducherry, Pondicherry, India
Nfdcs Innovations (Opc) Private Limited U74999WB2017OPC222930 Kolkata, West Bengal, India
Wellabet Medsolutions Private Limited U74999TN2012PTC087925 Chennai, Tamil Nadu, India
Ethx U74994DL2017PTC324094 New Delhi, Delhi, India
Cocoweave Work Cafe Private Limited U74999DL2018PTC327863 Delhi, Delhi, India
Onkar Dealer Private Limited U51109WB2007PTC119609 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Kosei Pharma Private Limited before audits and certifications: compliance score 43/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Kosei Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Kosei Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 61/100, distress signals and MSME payment-delay disclosures - know whether Kosei Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Kosei Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Kosei Pharma Private Limited an active company?

Kosei Pharma Private Limited has MCA status “Under Process Of Striking Off” with a compliance score of 43/100 (Caution Indicated).

Is Kosei Pharma Private Limited financially healthy?

Kosei Pharma Private Limited has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Kosei Pharma Private Limited?

Its overall Trust Score is 61/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Kosei Pharma Private Limited?

The ultimate holding entity is Kosei Pharma(uk) Limited. 2 active director(s) are on record.

Does Kosei Pharma Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Kosei Pharma Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 43/100 (Caution Indicated).

Is it risky to lend to Kosei Pharma Private Limited?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.